Omar Khateeb speaks with Nishant Doctor, Founder, CEO, and CTO of Surf Therapeutics, about the next frontier of neurotechnology: using ultrasound neuromodulation to target inflammation.Nishant breaks down the science behind the cholinergic anti-inflammatory pathway, why the splenic nerve may offer a more direct target than the vagus nerve, and how non-invasive stimulation could create a different treatment path for rheumatoid arthritis patients.The episode also covers capital efficiency, first-in-human studies, patient usability, autoimmune disease, and why Surf is focused on building a therapy that could be safer, easier, and more accessible than invasive alternatives.A powerful conversation on bioelectronic medicine, chronic disease, and the future of non-invasive MedTech.
This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.
Episode Breakdown
00:00 How One Minute of Stimulation Can Reduce Inflammation
01:34 Intro + Why Drug Alternatives Matter
03:23 Nishant Doctor’s Journey Into Neuromodulation
05:23 Neuromodulation vs Neurotechnology Explained
08:15 Neuralink, BCI, and the Rise of NeuroTech
09:07 Building Through Market Cycles
13:37 The Origin Story of Surf Therapeutics
15:23 Inflammation, Healthspan, and Chronic Disease
17:52 The Science Behind the Anti-Inflammatory Pathway
18:50 Why Vagus Nerve Stimulation Works
20:18 Why Surf Chose a Non-Invasive Approach
21:31 The Problem with Current Treatment Options
22:44 Going Directly to the Splenic Nerve
24:26 Vagus Nerve Side Effects Explained
26:03 Biohacking, Longevity, and Vagus Nerve Devices
27:15 How Surf’s Technology Works
29:40 Capital Efficiency and Startup Execution
32:02 Why Testing Beats Product Perfection
33:58 Build Fast, Test Fast, Learn Fast
37:20 Why Rheumatoid Arthritis Was the First Target
39:38 The Rheumatoid Arthritis Opportunity
40:02 Understanding Rheumatoid Arthritis
41:38 Expanding Beyond a Single Disease
43:31 The Future of Inflammation Therapy
44:55 Why the Company is Called Surf
46:16 Clinical Progress and Upcoming Milestones
48:02 Strategic Interest and Future Opportunities
48:38 Outro
Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.
Subscribe to our Youtube Channel
https://www.youtube.com/@thestateofmedtech
Subscribe to our LinkedIn Newsletter
https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
Follow The State of MedTech on
LinkedIn https://www.linkedin.com/company/thestateofmedtech/
Instagram https://www.instagram.com/stateofmedtech/
TikTok https://www.tiktok.com/@stateofmedtechpod
X https://x.com/stateofmedtech
Facebook https://www.facebook.com/stateofmedtech
Follow Omar M. Khateeb on
LinkedIn https://www.linkedin.com/in/okhateeb/
Instagram https://www.instagram.com/omar.m.khateeb/
TikTok https://www.tiktok.com/@omar.m.khateeb
X https: https://x.com/OmarMKhateeb
Facebook https://www.facebook.com/OmarMKhateeb
#neurotech #neuromodulation #rheumatoidarthritis #medtech #healthcareinnovation
